Current Delivery of Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery (CS/HIPEC) and Perioperative Practices: An International Survey of High-Volume Surgeons

[1]  M. Schwab,et al.  Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer , 2018, Journal of clinical medicine.

[2]  Michael W. Bishop,et al.  Anesthesia and Pain Management for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Desmoplastic Small Round Cell Tumors in Children, Adolescents, and Young Adults , 2018, Annals of Surgical Oncology.

[3]  Y. Ko,et al.  Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons , 2018, World Journal of Surgical Oncology.

[4]  A. Friggeri,et al.  No impact on long-term survival of prolonged ICU stay and re-admission for patients undergoing cytoreductive surgery with HIPEC. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  A. Govindarajan,et al.  Impact of Major Complications on Patients’ Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy , 2016, Annals of Surgical Oncology.

[6]  K. Turaga,et al.  Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. , 2016, Journal of gastrointestinal oncology.

[7]  R. Seshadri,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. , 2016, World journal of gastroenterology.

[8]  L. Bosserman,et al.  American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology. , 2016, Journal of oncology practice.

[9]  J. Spiliotis,et al.  Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study , 2015, Annals of Surgical Oncology.

[10]  Ying Ding,et al.  Institutional Learning Curve of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Malignancies , 2015, Annals of Surgical Oncology.

[11]  J. Overbey,et al.  Escalation of Socioeconomic Disparities Among Patients with Colorectal Cancer Receiving Advanced Surgical Treatment , 2015, Annals of Surgical Oncology.

[12]  R. Howard,et al.  Psychological Prehabilitation Before Cancer Surgery: A Systematic Review , 2015, Annals of Surgical Oncology.

[13]  M. Wiezer,et al.  Cytoreductive surgery and HIPEC in treatment of colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists , 2015, International Journal of Clinical Oncology.

[14]  K. Havenga,et al.  Implementation of a Standardized HIPEC Protocol Improves Outcome for Peritoneal Malignancy , 2015, World Journal of Surgery.

[15]  D. Morris,et al.  Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei , 2014, The British journal of surgery.

[16]  A. Mirnezami,et al.  Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. , 2014, World journal of gastroenterology.

[17]  Yong Shao,et al.  The enhanced recovery after surgery (ERAS) pathway for patients undergoing colorectal surgery: an update of meta-analysis of randomized controlled trials , 2012, International Journal of Colorectal Disease.

[18]  A. Stojadinovic,et al.  The American Society of Peritoneal Surface Malignancies (ASPSM) , 2011, Annals of Surgical Oncology.

[19]  T. Chua,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Esquivel,et al.  Learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy , 2009, Journal of surgical oncology.

[21]  M. Choti,et al.  NCCN Clinical Practice Guidelines in Oncology: colon cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  M. Huo,et al.  Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. , 2009, Clinical therapeutics.

[23]  T. Chua,et al.  Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and Mortality , 2009, Annals of surgery.

[24]  D. Morris,et al.  A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin , 2009, Annals of Surgical Oncology.

[25]  B. Moran,et al.  Morbidity and Mortality With Cytoreductive Surgery and Intraperitoneal Chemotherapy: The Importance of a Learning Curve , 2009, Cancer journal.

[26]  Jolene D Smyth,et al.  Internet, Mail, and Mixed-Mode Surveys: The Tailored Design Method , 2008 .

[27]  D. Coit,et al.  Long-term Survival Following Treatment of Pseudomyxoma Peritonei: An Analysis of Surgical Therapy , 2005, Annals of surgery.

[28]  C. Roland,et al.  Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates. , 2016, The Journal of surgical research.

[29]  N. Petrelli,et al.  Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States , 2013, Annals of Surgical Oncology.